A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
Completed
ChemoCentryx
Phase 3
2017-03-15
The aim of the trial is to assess the safety and efficacy of the orally-administered,
selective complement C5a receptor inhibitor CCX168 (avacopan) in inducing and sustaining
remission in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
(AAV).
Controlled Trial Evaluating Avacopan in C3 Glomerulopathy
Active, not recruiting
Medpace, Inc.
Phase 2
2017-09-29
The aim of this trial is to evaluate the effect of avacopan treatment on renal disease
activity in patients with complement component 3 glomerulopathy (C3G). Funding Source - FDA
OOPD
Controlled Trial Evaluating Avacopan in C3 Glomerulopathy
Active, not recruiting
ChemoCentryx
Phase 2
2017-09-29
The aim of this trial is to evaluate the effect of avacopan treatment on renal disease
activity in patients with complement component 3 glomerulopathy (C3G). Funding Source - FDA
OOPD
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
Recruiting
Amgen
Phase 4
2024-02-07
The primary objective of this study is to evaluate the long-term safety of avacopan in
participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Single Dose of Simvastatin
COMPLETED
Amgen
PHASE1
2022-06-28
The primary objective of this clinical study is to evaluate the effect of repeated oral doses of avacopan (30 mg and 60 mg twice daily approximately 12 hours apart \[BID\]) given under fed conditions on the PK of a single dose of simvastatin (40 mg) in healthy volunteers.
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
RECRUITING
Amgen
PHASE3
2024-10-22
The main objective of this study is to explore the efficacy of avacopan in participants affected by AAV.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
